Human immunoglobulin E specific for house dust mite allergens (HDM-specific IgE)

Human immunoglobulin E (IgE) specific for house dust mite (HDM) allergens is a primary driver of Type I hypersensitivity reactions in individuals sensitized to mites such as Dermatophagoides pteronyssinus and Dermatophagoides farinae (NIH, 2017). These antibodies are produced by B cells and circulate in the blood before binding to high-affinity FcεRI receptors on the surface of mast cells and basophils (ERS, 2021). When a sensitized individual is exposed to HDM allergens, the allergens cross-link the receptor-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (Drugs.com, 2025). This cascade results in clinical symptoms of allergic rhinitis, asthma, and atopic dermatitis (NIH, 2022). Therapeutic strategies targeting this pathway include the use of monoclonal antibodies like omalizumab to sequester free IgE and prevent receptor binding (ResearchGate, 2025). Additionally, allergen-specific immunotherapy (AIT) aims to induce immunological tolerance and promote the production of protective IgG4 antibodies that compete with IgE for allergen binding (Frontiers in Immunology, 2022).

Other names

House dust mite specific IgEHDM-sIgEAnti-HDM IgEDermatophagoides pteronyssinus specific IgEDermatophagoides farinae specific IgE

Anti-IgE monoclonal antibodies, such as omalizumab, bind to the Cε3 domain of free circulating IgE, preventing its interaction with high-affinity FcεRI receptors on mast cells and basophils (ResearchGate, 2025). This sequestration reduces the density of receptors on effector cells and inhibits the release of inflammatory mediators upon allergen exposure (NIH, 2025). Allergen-specific immunotherapy (AIT) works by inducing immune tolerance, shifting the antibody response from IgE to IgG4, which acts as a blocking antibody to prevent IgE-allergen binding (Frontiers in Immunology, 2022).